To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
Within the Institute, the "Funding Research and Technology Transfer" team is at your disposal to identify the scientists and the skills you need to set up a joint project, to define the terms of a collaboration contract or study.
Whether you are an academic, a SME or an industrialist, our team informs and advices you about the possibilities of consortium assembly, technology transfer, patent licensing or use of our platforms.
The team is also at the disposal of the researchers of the institute to accompany them in achieving their valorization objectives.
All the news of the Institute of life sciences Frédéric Joliot
Scientific result | Article | Antibiotics
The recent publication, in the journal Diagnostics, of a collaborative study associating AP-HP, NG-Biotech and a team from the Institute, is an opportunity to recall the Institute's commitment to the development of means of detecting antimicrobial resistance, a global phenomenon in the WHO's sights, as recalled by the World Antimicrobial Awareness Week.
The World Health Organization organizes every year, from November 18 to 24, a week to raise awareness of the global phenomenon of antimicrobial resistance, particularly to antibiotics. The aim is "to encourage citizens, health workers and decision-makers to adopt best practices to prevent the emergence of antimicrobial resistance and the spread of current resistance" (source: WHO).
The “Laboratoire d'Etudes et de Recherches en Immunoanalyse” (LERI) has been involved for several years in the development of effective means of detecting antimicrobial-resistant bacterial strains. Together with NG Biotech and a team from AP-HP, LERI has recently developed new tests for the detection of several groups of bacterial enzymes responsible for antibiotic resistance. These test strips have major advantages: simplicity, low cost, sensitivity, speed. They enable the detection of β lactamases in only 15 minutes from a blood culture, where current methods require several hours. Europe made no mistake: since 2018, it has been funding a consortium involving the three entities and other European partners via the EIT Health funding tool (successive projects BL DetecTool and AMR-DetecTool).
Among the tests developed, the CTX-M MULTI test, already marketed by NG-Biotech, allows the simultaneous detection of 5 groups of beta-lactamases (CTX-M of groups 1, 2, 8, 9 and 25), which confer resistance to beta-lactam antibiotics, among the most prescribed antibiotics.
In an article published in Diagnostics, the collaborators validated the CTX-M MULTI test. On the one hand, the test showed 100% sensitivity and specificity on a collection of enterobacteria colonies already characterized (by PCR) for their beta-lactamase content. On the other hand, it was able to detect 98% of the enterobacteria producing a broad spectrum of beta-lactamases (ESBL) identified from colonies or blood cultures at the Bicêtre hospital. The use of this test should therefore improve the management of antimicrobial control, particularly in the hospital environment, by reducing the inappropriate use of beta-lactam antibiotics.
S. Bernabeu, Kayaththiry C. Ratnam, H. Boutal, C. Gonzalez, A. Vogel, K. Devilliers, M. Plaisance, S. Oueslati, S. Malhotra-Kumar, L. Dortet, N. Fortineau, S. Simon, H. Volland and Thierry Naas. A Lateral Flow Immunoassay for the Rapid Identification of CTX-M-Producing Enterobacterales from Culture Plates and Positive Blood Cultures. | Diagnostics, 2020, 10, 764
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.